Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Large Drop in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBTGet Free Report) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 30,400 shares, a drop of 61.4% from the November 15th total of 78,800 shares. Approximately 7.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,400,000 shares, the short-interest ratio is presently 0.0 days.

Avalon GloboCare Stock Performance

Avalon GloboCare stock traded down $0.26 during midday trading on Friday, reaching $4.57. 89,980 shares of the company were exchanged, compared to its average volume of 511,415. The company has a market capitalization of $4.98 million, a price-to-earnings ratio of -0.23 and a beta of 0.27. The firm’s 50-day simple moving average is $3.15 and its 200-day simple moving average is $4.74. Avalon GloboCare has a 1 year low of $2.11 and a 1 year high of $21.60.

Avalon GloboCare Company Profile

(Get Free Report)

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.

Featured Stories

Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.